BMO Capital Markets Increases Valeant Pharmaceuticals International, Inc. (VRX) Price Target to $17.00

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) had its price target boosted by BMO Capital Markets from $16.00 to $17.00 in a research note issued to investors on Monday. The firm currently has a “market perform” rating on the specialty pharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 19.05% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Canaccord Genuity set a $14.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Thursday, August 10th. Rodman & Renshaw restated a “neutral” rating and issued a $17.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Piper Jaffray Companies restated a “sell” rating and issued a $14.00 price target on shares of Valeant Pharmaceuticals International in a research note on Sunday, September 17th. Wells Fargo & Company restated an “underperform” rating and issued a $9.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $18.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Five research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Valeant Pharmaceuticals International presently has an average rating of “Hold” and a consensus target price of $17.22.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at $14.28 on Monday. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $18.65. The stock has a market capitalization of $5,089.44, a P/E ratio of 2.37, a PEG ratio of 0.40 and a beta of -0.40. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26.

COPYRIGHT VIOLATION NOTICE: “BMO Capital Markets Increases Valeant Pharmaceuticals International, Inc. (VRX) Price Target to $17.00” was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://weekherald.com/2017/11/15/bmo-capital-markets-increases-valeant-pharmaceuticals-international-inc-vrx-price-target-to-17-00.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average cost of $14.33 per share, with a total value of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.87% of the company’s stock.

Several hedge funds have recently made changes to their positions in VRX. Ameriprise Financial Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 31.3% during the first quarter. Ameriprise Financial Inc. now owns 44,149 shares of the specialty pharmaceutical company’s stock valued at $487,000 after purchasing an additional 10,534 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Valeant Pharmaceuticals International by 49.3% during the first quarter. Alliancebernstein L.P. now owns 39,664 shares of the specialty pharmaceutical company’s stock valued at $437,000 after purchasing an additional 13,092 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 33.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Valeant Pharmaceuticals International by 9.8% during the first quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock valued at $76,990,000 after purchasing an additional 621,618 shares in the last quarter. Finally, Paloma Partners Management Co boosted its stake in shares of Valeant Pharmaceuticals International by 12.0% during the first quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock valued at $310,000 after purchasing an additional 2,996 shares in the last quarter. 46.61% of the stock is currently owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply